GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nippon Shinyaku Co Ltd (TSE:4516) » Definitions » Total Equity

Nippon Shinyaku Co (TSE:4516) Total Equity : 円220,534 Mil (As of Mar. 2024)


View and export this data going back to 1962. Start your Free Trial

What is Nippon Shinyaku Co Total Equity?

Nippon Shinyaku Co's total equity for the quarter that ended in Mar. 2024 was 円220,534 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Nippon Shinyaku Co Total Equity Historical Data

The historical data trend for Nippon Shinyaku Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nippon Shinyaku Co Total Equity Chart

Nippon Shinyaku Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 146,860.00 163,448.00 180,884.00 195,931.00 220,534.00

Nippon Shinyaku Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 195,931.00 202,798.00 211,773.00 215,316.00 220,534.00

Nippon Shinyaku Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nippon Shinyaku Co's Total Equity for the fiscal year that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=263404-42870
=220,534

Nippon Shinyaku Co's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=263404-42870
=220,534

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nippon Shinyaku Co Total Equity Related Terms

Thank you for viewing the detailed overview of Nippon Shinyaku Co's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Nippon Shinyaku Co (TSE:4516) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nippon Shinyaku Co Ltd (TSE:4516) » Definitions » Total Equity
Comparable Companies
TSE:4530 TSE:4581 TSE:4887 TSE:4540 TSE:4506 TSE:4547 TSE:4553 TSE:4521 TSE:4534 TSE:4551 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
NPPNY:USA
Address
14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku, Kyoto, JPN, 601-8550
Website
http://www.nippon-shinyaku.co.jp
Nippon Shinyaku Co Ltd is a specialty and generic drug manufacturing company. Nippon's research and development activities include a focus on pharmaceuticals, nutraceuticals, safety and pharmacokinetics of drug seeds, genomic drug discovery, and nucleic acid drugs. The company also develops health food ingredients, preservatives, protein preparations, and spices. Nippon considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Nippon Shinyaku Co (TSE:4516) Headlines

No Headlines